{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-23-000003","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.956877+00:00","generated_at":"2026-06-20T13:08:49.509159+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"LivaNova RECOVER depression trial enrollment to continue to 450 patients per DSMB advice","bullets":["Independent Statistical Analysis Committee advised enrollment continue from 425 to 450 unipolar patients.","Trial remains on track; interim analyses every 25 patients assess predictive probability of success.","If successful, results could support peer-reviewed article and CMS reimbursement reconsideration for VNS Therapy.","No efficacy or safety signal disclosed; trial continues per protocol."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-23-000003","json":"https://secwatch.observer/filing/0001639691-23-000003.json","markdown":"https://secwatch.observer/filing/0001639691-23-000003.md","text":"https://secwatch.observer/filing/0001639691-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000003/0001639691-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000003/livn-20230118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:08:49.509159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}